Managing Atrial Fibrillation

Documents to Request

• 12-lead ECG confirming AF or recent Holter/event monitor
• Echocardiogram (LA size, LVEF, valve disease)
• Current medication list
• Recent labs: CBC, BMP, TSH, INR (if on warfarin), hepatic function
• Prior cardioversion or ablation procedure notes
• Bleeding history and any contraindications to anticoagulation
• CHA2DS2-VASc and HAS-BLED component documentation

Step 1: AF Classification and CHA2DS2-VASc Scoring

2023 AF Classification:

CHA2DS2-VASc Score Calculation:

Anticoagulation Decision:

Step 2: Anticoagulation Selection

DOACs (preferred over warfarin per 2023 guidelines):

Warfarin Indications (when DOACs are contraindicated):

• Mechanical heart valve
• Moderate-to-severe mitral stenosis
• CrCl < 15 mL/min (or dialysis) — though apixaban has data in ESRD
• Antiphospholipid syndrome
• Target INR 2.0–3.0; TTR goal > 70%

HAS-BLED Score (Bleeding Risk Assessment):

• Hypertension, Abnormal renal/liver function, Stroke, Bleeding history, Labile INR, Elderly (> 65), Drugs/alcohol
• Score ≥ 3 = high bleeding risk → does NOT contraindicate anticoagulation; rather, mandates closer monitoring and modifiable risk factor correction

Step 3: Rate Control Strategy

Target: Resting HR < 110 bpm (lenient) or < 80 bpm (strict if symptomatic)

First-line Agents:

• In HFrEF: beta-blockers preferred; avoid CCBs. Digoxin may be added if beta-blocker insufficient.
• Amiodarone for rate control only as last resort (toxicity profile).
• AV node ablation + pacemaker for refractory rate control in permanent AF.

Step 4: Rhythm Control Strategy

2023 Guideline Shift — Earlier Rhythm Control: The EAST-AFNET 4 trial demonstrated that early rhythm control (within 12 months of diagnosis) reduces cardiovascular death, stroke, and hospitalization compared to rate control alone.

Antiarrhythmic Drug Selection:

Catheter Ablation (Class I for symptomatic AF refractory to ≥ 1 AAD):

• Pulmonary vein isolation (PVI) is the cornerstone technique
• CASTLE-AF: ablation in HFrEF reduces mortality and HF hospitalization
• May be considered first-line in selected patients (Class IIa)

Cardioversion Protocol:

• If AF duration > 48 hours or unknown: 3 weeks anticoagulation pre-cardioversion OR TEE to exclude LAA thrombus
• 4 weeks anticoagulation post-cardioversion minimum; long-term based on CHA2DS2-VASc

Step 5: Special Populations and Monitoring

Post-operative AF: May be self-limited; short-term rate control and anticoagulation for 30–60 days. AF with WPW: Avoid AV nodal blockers (digoxin, CCBs, adenosine); use procainamide or ibutilide. AF with RVR causing hemodynamic instability: Emergent synchronized cardioversion.

Ongoing Monitoring:

• Symptom assessment using EHRA score at each visit
• Annual TFTs and LFTs if on amiodarone; CXR and PFTs every 6–12 months
• Renal function monitoring for DOAC dose adjustments (annually or more if declining)
• LA size surveillance on echo — progressive dilation suggests inadequate rhythm control

Checkpoint B: Post-Draft Alignment (Mandatory)

1. Is the CHA2DS2-VASc score calculated with all components documented?
2. Is the anticoagulation decision aligned with the score and documented?
3. Is the rate vs. rhythm control strategy explicitly justified?
4. Are antiarrhythmic drug contraindications checked against cardiac structure?
5. Is a cardioversion/ablation plan included or deferred with rationale?

Quality Audit

• AF type classified per 2023 guidelines
• CHA2DS2-VASc score calculated with individual components listed
• Anticoagulation initiated, deferred, or contraindicated with documentation
• DOAC selected with appropriate dose and renal adjustment
• HAS-BLED calculated and modifiable risk factors addressed
• Rate control target and agent documented
• Rhythm control considered with AAD selection or ablation referral
• Structural heart disease assessed before AAD selection
• Cardioversion anticoagulation protocol followed if applicable
• LVEF assessed for tachycardia-mediated cardiomyopathy
• Thyroid function checked (AF can be caused by hyperthyroidism)
• Follow-up plan includes symptom, rate, and anticoagulation monitoring
• Left atrial appendage occlusion considered if anticoagulation contraindicated

Guidelines

1. DOACs are preferred over warfarin for non-valvular AF in all patients without mechanical valves or moderate-to-severe mitral stenosis.
2. A CHA2DS2-VASc score of 0 in males (1 in females from sex factor alone) means no anticoagulation — do not overtreat.
3. High HAS-BLED score is not a reason to withhold anticoagulation — it is a prompt to address modifiable bleeding risk factors.
4. Never use flecainide or propafenone in patients with structural heart disease, prior MI, or HFrEF — proarrhythmic risk is prohibitive.
5. Amiodarone is the most effective AAD but has cumulative toxicity — reserve for patients who cannot tolerate or have failed other agents.
6. Early rhythm control (within 12 months of AF diagnosis) is now supported by trial evidence and should be offered to symptomatic patients.
7. Anticoagulation decisions should be independent of the rate vs. rhythm strategy — stroke risk persists regardless of rhythm control success.
8. Always document the clinical rationale for choosing rate control over rhythm control or vice versa.